Paper Details

  1. Home
  2. Paper Details

Changes in plasma lipids predict pravastatin efficacy in secondary prevention.

Author: , AlshehryZahir H, BarlowChristopher K, BarnesElizabeth H, ChalmersJohn, GilesCorey, HillisGraham S, HuynhKevin, JayawardanaKaushala S, KingwellBronwyn A, KirbyAdrienne, MarschnerIan C, McConvilleMalcolm J, MeiklePeter J, MellettNatalie A, MundraPiyushkumar A, NestelPaul J, SimesJohn, SullivanDavid R, ThompsonPeter, TonkinAndrew M, WongGerard, WoodwardMark, ZoungasSophia

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study examined the changes in lipids upon pravastatin treatment and its relationship with risk reduction for future cardiovascular events. The change in the lipid ratio PI(36:2)/PC(38:4) was found to be a potential biomarker for monitoring the clinical benefit of statin treatment.
Paper Details　
Original Abstract of the Article :
BACKGROUNDStatins have pleiotropic effects on lipid metabolism. The relationship between these effects and future cardiovascular events is unknown. We characterized the changes in lipids upon pravastatin treatment and defined the relationship with risk reduction for future cardiovascular events.METH...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6629250/

データ提供：米国国立医学図書館（NLM）

Predicting Pravastatin Efficacy in Secondary Prevention

Statins, a class of drugs commonly used to lower cholesterol levels, have been shown to reduce the risk of cardiovascular events. This study explores the relationship between lipid metabolism and the effectiveness of pravastatin treatment in secondary prevention of cardiovascular events. The researchers investigated the changes in lipid profiles upon pravastatin treatment and their association with future cardiovascular events, aiming to identify potential biomarkers for predicting treatment efficacy.

Lipid Metabolism and Cardiovascular Health

The study reveals that changes in specific lipid species, particularly those containing arachidonic acid and phosphatidylinositol, can predict the effectiveness of pravastatin treatment in secondary prevention. These findings suggest that monitoring these lipid profiles could be a valuable tool for personalizing statin therapy and optimizing patient outcomes.

Personalized Medicine for Cardiovascular Health

Just as a camel adapts to the changing conditions of the desert, our bodies are constantly adjusting to internal and external influences. This study emphasizes the importance of individualized approaches to cardiovascular health, using lipid profiles to personalize statin therapy and improve the effectiveness of treatment.

Dr. Camel's Conclusion

This study explores the relationship between lipid metabolism and the effectiveness of pravastatin treatment in secondary prevention of cardiovascular events. The research identifies specific lipid species that can predict treatment efficacy, suggesting that monitoring these profiles could be a valuable tool for personalizing statin therapy and optimizing patient outcomes.

Date :
  1. Date Completed 2020-07-21
  2. Date Revised 2020-07-21
Further Info :

Pubmed ID

31292301

DOI: Digital Object Identifier

PMC6629250

Related Literature

Article Analysis
・Effects of pravastatin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.